Drug intelligence / Profile preview

Rupishu

Development stage: Unknown
Lead developer: Xi'an Qianhe Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Rupishu is a proprietary Traditional Chinese Medicine (TCM) developed and manufactured by Xi'an Qianhe Pharmaceutical. Formulated as an oral capsule, it is primarily indicated for the treatment of breast hyperplasia (lobular hyperplasia of the mammary gland) and associated symptoms such as mastalgia (breast pain) and the presence of breast lumps. According to traditional pharmacological principles, the herbal formulation works by soothing the liver, regulating qi, promoting blood circulation, and dissipating nodules. As a complex herbal product, its therapeutic effects are attributed to the synergistic action of multiple phytochemical constituents rather than a single molecular target. It is currently approved and marketed in China.

Brand names: Rupishu
Other names: 乳癖舒胶囊Rupishu CapsulesRupishu Jiaonang

Beyond the preview

Go deeper on Rupishu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rupishu.

Explore the full profile